BioSpace News Archive

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”) today presented new studies highlighting the significant impact of GAD in the US at ISPOR 2024, the leading global conference for health economics and outcomes research (HEOR) being held this week in Atlanta.

May 9, 2024
·
11 min read
Business

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

Monopar Therapeutics Inc., a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, announced first quarter 2024 financial results and summarized recent developments.

May 9, 2024
·
7 min read
Drug Development

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

TScan Therapeutics, Inc. announced that the first patient has been dosed in the Company’s Phase 1 trial evaluating TCR-T therapy for the treatment of solid tumors.

May 9, 2024
·
7 min read
Business

Applied Therapeutics Reports First Quarter 2024 Financial Results

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, reported financial results for the first quarter ended March 31, 2024.

May 9, 2024
·
11 min read
Business

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, reported business highlights and financial results for the first quarter ending March 31, 2024.

May 9, 2024
·
19 min read
Biotech Bay

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline

Bluejay Therapeutics, a leader in the development of novel therapeutics, announced the successful closure of a $182 million Series C financing round.

May 9, 2024
·
2 min read
Business

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Aura Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

May 9, 2024
·
12 min read
Business

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics, Inc. announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.

May 9, 2024
·
11 min read
Bio NC

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

Verona Pharma plc, announces it and its wholly-owned subsidiary, Verona Pharma, Inc., have entered into strategic financing agreements providing access to up to $650 million from funds managed by Oaktree Capital Management, L.P. and OMERS Life Sciences.

May 9, 2024
·
10 min read
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals.

May 9, 2024
·
10 min read